New Cross Hospital

Running trials

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

  NCT07136467· AbbVie· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Hoffmann-La Roche· Source

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Post-Market Clinical Follow Up Study With Navitor Valve

  NCT06008080· Abbott Medical Devices· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  GEKO Venous Thromboembolism Prevention Study

  NCT05476913· Firstkind Ltd· Source

• Recruiting

  RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

  NCT05568069· University Hospital Southampton NHS Foundation Trust· Source

• Active, not recruiting

  A Study of Daratumumab

  NCT05438043· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

  NCT05494606· AbbVie· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

  NCT04663750· Phase 3· King's College Hospital NHS Trust· Source

• Recruiting

  iCorMicA - Stratified Medicine in Angina

  NCT04674449· NHS Greater Glasgow and Clyde· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· University of Leicester· Source

• Recruiting

  MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

  NCT04116502· Phase 3· University of Birmingham· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

• Active, not recruiting

  Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

  NCT02406222· Phase 2· University of Leeds· Source

• Active, not recruiting

  Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

  NCT01566240· Phase 3· University College, London· Source

• Active, not recruiting

  Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

  NCT00268476· Phase 2/3· Medical Research Council· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Multiple myeloma3 recruiting
• Aortic stenosis2 recruiting
• Heart failure2 recruiting
• Acute myeloid leukaemia1 recruiting
• Alopecia areata1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Hidradenitis suppurativa1 recruiting
• Macular degeneration1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Primary biliary cholangitis1 recruiting
• Stroke1 recruiting
• Vitiligo1 recruiting

Closed trials

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

  NCT05848258· Phase 2· Eli Lilly and Company· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

  NCT04619797· Phase 2/3· Hoffmann-La Roche· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)

  NCT03269110· Ottawa Hospital Research Institute· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· King's College Hospital NHS Trust· Source

• Completed

  A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

  NCT01897480· Phase 2· Eli Lilly and Company· Source

• Completed

  Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

  NCT01842568· Population Health Research Institute· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Alopecia areata6 works · 1 trial
• Vitiligo5 works · 2 trials